Introduction
In 2013, two groups independently identified a rare variant in TREM2 (p.R47H) that increased risk for AD almost three-fold, which is the strongest genetic risk factor for late-onset AD since the identification of APOE ε4 30 years earlier (1, 2). TREM2 p.R47H has also been associated with clinical, imaging, and neuropathological AD phenotypes, including advanced behavioral symptoms, gray matter atrophy, and Braak staging (3, 4) . Since then, additional rare variants in TREM2 have been associated with AD risk including p.R62H, p.H157Y, p.R98W, p.D87N, p.T66M, p.Y38C, and p.Q33X (1, 5-7).
TREM2 encodes a protein that is part of a transmembrane receptor-signaling complex essential for the immune response of myeloid cells such as microglia. TREM2 is highly and specifically expressed in microglia in the central nervous system (CNS) where it plays a key role in microglial activation, survival, and phagocytosis (8) (9) (10) (11) . Recent evidence from animal models of AD suggest that TREM2 has a complex relationship with the key proteins involved in AD pathogenesis, amyloid-β and tau. There is conflicting studies about the role of TREM2 in amyloid-beta (Aβ) pathology. TREM2 has been associated with phagocytosis in the presence of Aβ (12) . Plaque-associated neuritic dystrophy was more severe (13, 14) and neuron loss was exaggerated in mice deficient for TREM2, in a gene-dose dependent manner (9) . Elevating levels of TREM2 through the introduction of a human TREM2 transgene reduced pathology and rescued cognitive function in amyloid-bearing mice (15) . On the other hand, a common phenotype across mouse models of amyloidosis is that reduction or loss of Trem2 leads to fewer amyloid plaque-associated microglia (9, 14, 16) . Other studies indicate that Trem2 deficiency protects against neurodegeneration through a dampened microglial-response to tau pathology (17, 18) .
In addition to the full-length TREM2 that makes up part of the transmembrane receptor, there is a soluble form of TREM2 (sTREM2) that may be produced by alternative splicing or proteolytic cleavage of the full-length protein (6, 12, 19) . Three distinct transcripts for TREM2 were found in human brain tissue, including a short transcript alternatively spliced to exclude exon 4 thus encoding the transmembrane domain predicted for sTREM2 (6) . Recently a cleavage site was identified on TREM2 that can be targeted by ADAM10, ADAM17, gamma-secretase, and possibly other proteases, to generate sTREM2 (20, 21) . sTREM2 is released into the cerebrospinal fluid (CSF) where it can be quantified (12, (22) (23) (24) (25) (26) (27) . CSF sTREM2 levels are hypothesized to increase in response to microglia activation due to neurodegenerative processes (23, 26) . Our group and others have demonstrated that CSF sTREM2 levels are elevated in AD (22, 23, 25) . Changes in CSF sTREM2 appear to occur after amyloid accumulation, beginning approximately five years before clinical symptom onset in autosomal dominant forms of AD (24) . Additionally, CSF sTREM2 levels are positively correlated with CSF tau and ptau levels, but not with CSF Aβ 42 , suggesting that sTREM2 may be associated with pathological processes occurring after the accumulation of Aβ (22, 23, 25) . Thus, CSF sTREM2 levels represent an important and dynamic biomarker of disease processes throughout AD pathogenesis.
Our group and others have shown that using CSF biomarkers of complex diseases as quantitative endophenotypes can identify genes that contribute to key biological pathways involved in disease (28) (29) (30) . In this study, we aimed to identify genetic modifiers of CSF sTREM2 levels. We conducted a genome wide association study (GWAS) of CSF sTREM2 levels from more than 1,390 individuals and have successfully detected a locus within the MS4A gene region (11q12.2) that shows novel genome-wide significant association with sTREM2 levels. We have also used bioinformatic, transcriptomic, and cellular approaches to test association between MS4A genes and TREM2. Based on these findings, we propose that the MS4A gene family contains a key regulator of sTREM2.
Results
The goal of this study was to identify genetic modifiers of CSF sTREM2 levels and to better understand the role of sTREM2 in biological pathways relevant to AD. To accomplish this goal, we analyzed genetic data and CSF sTREM2 levels from 813 individuals from the Alzheimer's Disease Neuroimaging Initiative (ADNI) in a genome-wide association study. We then sought to replicate our findings in independent datasets (n= 580).
CSF sTREM2 levels correlates with age, sex, and AD biomarkers
We analyzed the largest dataset to date for CSF sTREM2 levels. The discovery cohort was obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) study (N = 813).
The levels of CSF sTREM2 in our analyses approximated a normal distribution without transformation. There were 606 AD cases and 207 cognitively normal controls in based on clinical diagnosis, none of whom carried previously identified risk mutations in TREM2 (Table   1) .
We tested the correlation between age at the time of lumbar puncture (LP) and CSF sTREM2 levels and found a positive correlation, consistent with our previous reports (Pearson r = 0.270, P = 4.66×10 -15 ; Supplementary Figure S1 ) (23) . We also tested CSF sTREM2 levels stratified by sex to determine whether sTREM2 levels were higher in males than females, as previously reported (23) (24) (25) 31) . There was no significant difference between CSF sTREM2 levels in males (3,926 ± 1,969 pg/mL) versus females (3,873 ± 1,856 pg/mL, one-tailed P = 0.347; Fig S1) . CSF sTREM2 levels were positively correlated with CSF tau (r = 0.377, P = 9.59×10 -29 ) and ptau levels (r = 0.348, P = 2.08×10 -24 ; Fig S1) . Consistent with our previous findings, there was no significant correlation between CSF sTREM2 levels and CSF Aβ 42 levels (r = 0.074, P = 0.052; Fig S1) .
We also had CSF sTREM2 levels from 38 individuals heterozygous for TREM2 risk variants which were not included in the GWAS: p.D87N, p.L211P, p.R47H, p.R62H, and p.H157Y (Table 2 ). There was a significant difference in CSF sTREM2 levels between TREM2 risk variant carriers (P = 0.042) as reported previously (23) . CSF sTREM2 levels were significantly lower in p.L211P carriers (2,578 ± 1,444 pg/mL) compared to non-carriers (3,903 ± 1,919 pg/mL, P = 0.026; Supplementary Figure S2 ). CSF sTREM2 levels were significantly elevated in p.R47H carriers (4,852 ± 1,172 pg/mL) compared to p.L211P carriers (P = 0.029) and p.D87N carriers (2,082 ± 239 pg/mL, P = 0.041), but they were not significantly different from non-carriers (P = 0.223; Fig S2) .
The MS4A gene region is associated with CSF sTREM2 levels
To identify genetic variants that influence CSF sTREM2, we tested for association between CSF sTREM2 levels and single-nucleotide polymorphisms (SNPs) with minor allele frequency (MAF) >0.02 using an additive linear regression model with age, sex, and two principal components (PCs) as covariates. A total of 7,320,475 genotyped and imputed variants passed strict quality control as described in the methods. TREM2 risk-variant carriers were excluded from the GWAS analyses. We replicated the association of rs1582763 with elevated CSF sTREM2 levels (z = 5.743, P = 9.28×10 -9 ; Figure 2) . A meta-analysis including the ADNI and the replication dataset showed a strong association between rs1582763 and CSF sTREM2 levels (P meta = 4.48×10 -21 ; Fig 2) .
Additionally, we replicated the association between rs6591561 (MS4A4A p.M159V) and reduced CSF sTREM2 levels in the independent dataset (z = -3.715, P = 2.03×10 -4 ). A meta-analysis with the ADNI discovery dataset provided a p-value of P = 1.65×10 -11 . Individual results for each dataset are shown in Supplementary Table S3 . Comparisons between MS4A association and APOE APOE genotype is the strongest genetic risk factor for AD (32) and APOE ε4 is the strongest genetic association for CSF Aβ 42 and tau levels (30, 33) . To determine whether APOE genotype is associated with CSF sTREM2 levels, we created a variable representing APOEmediated AD risk by recoding APOE genotype for each individual as 0 for ε2/ε2, 1 for ε2/ε3, 2 for ε3/ε3, 3 for ε2/ε4, 4 for ε3/ε4, and 5 for ε4/ε4. We added this APOE genotype risk variable to a regression model, adjusting for age, sex, and two PCs for population stratification, and found that APOE genotype was not significantly associated with CSF sTREM2 levels (β = -26.5, P = 0.613). The SNP commonly used as a proxy for APOE ε4, rs769449, was also not associated with CSF sTREM2 levels (β = -106.9, P = 0.308).
The influence of APOE genotype on Aβ pathology, and thereby biomarkers for Aβ pathology, including CSF Aβ42, has been a consistent finding (30, 34) . Within the same subset of individuals, the effect size of rs1582763 on CSF sTREM2 levels was similar (β = 0.366, P = 7.53×10 -13 ) to that of APOE on CSF Aβ 42 levels (β = -0.361, P = 1.69×10 -34 ). When comparing the lower vs. upper quartiles of CSF sTREM2 levels, rs1582763
had an OR = 3.34 for higher CSF sTREM2 (95% CI = 2.37 -4.82, P = 2.50×10 -11 ), which is similar to the effect of APOE on CSF Aβ 42 levels (OR = 2.84, 95% CI 2.30 -3.56). Thus, the impact of rs1582763, in the MS4A gene region, on CSF sTREM2 levels is similar to that of APOE, the major regulator of AD risk, on CSF Aβ 42 levels.
Additional genes associated with CSF sTREM2 levels
To identify genes associated with CSF sTREM2 levels, we used MAGMA, which maps every SNP to the closest gene, takes into account the LD structure, and uses multiple regression analyses to provide a p-value for the association of each gene with CSF sTREM2 levels. There were four genes associated with CSF sTREM2 levels and passed multiple test correction (P < 2.75×10 -6 ) All of those genes belong to the MS4A gene family. and included MS4A4A (P = 3.15×10 -11 ; Figure 3 ), MS4A4E (P = 6.13×10 -12 ), follMS4A2 (P = 1.29×10 -11 ), and MS4A6A (P = 1.44×10 -11 ). However there were also other genes, specifically, TREML2 that was near genewide significance with 89 mapped variants (P = 3.23×10 -6 ; Fig 3) , suggesting that there are other genes and regions that are associated with sTREM2 levels, although the effect size is not as large as the effect size for the MS4A gene region ).
Functional annotation of genome wide significant signals in the MS4A gene region
The genome-wide significant association with CSF sTREM2 levels is located in a gene- We first examined whether any of the genome-wide significant variants were located within exonic regions and identified two coding variants: the missense variant within MS4A4A rs6591561 (p.M159V, MAF = 0.316, β = -593.6, P = 1.47×10 We also searched for eQTL effects of rs1582763, the top SNP for CSF sTREM2 levels.
Rs1582763 produced an eQTL effect on MS4A6A in whole blood (GTEx: β = -0.089, P = 3.90×10 MS4A4A: β = -0.326, P = 1.10×10 -2 ; MS4A6A: β = -0.138, P = 3.32×10 -4 ). Together, this data suggests that the principle genes driving the GWAS signal for CSF sTREM2 levels may be MS4A4A, MS4A6A, or both.
MS4A genes and TREM2 gene expression are highly correlated
We tested for correlations between expression of TREM2 and members of the MS4A family using brain RNA-seq data from the Knight ADRC (N = 103) and DIAN (N = 19) (36) .
Among the 16 genes tested from the MS4A family, the expression of three genes (MS4A4A, ; Supplementary Figure S8 and Supplementary Table S6 ). These data further support that MS4A4A or MS4A6A may be the principle genes regulating CSF sTREM2 levels.
Targeting MS4A4A on human macrophages decreases levels of soluble TREM2 in vitro
MS4A4A and MS4A6A are both highly expressed in microglia (37) . However, the mouse ortholog for MS4A6A is Ms4a6e and there is no mouse ortholog for MS4A4A (38, 39) . Thus, to understand the role of MS4A genes on TREM2 function, it is essential to use human models. To begin evaluating the functional connection between TREM2 and MS4A4A and MS4A6A, we examined human macrophages, which are myeloid cells expressing TREM2 and can serve as a surrogate for microglia (40) .
To examine the therapeutic potential of targeting these MS4A proteins on sTREM2 levels, we used an antibody-based approach. Human macrophages were derived in vitro from blood monocytes and media from the cells was tested for the presence of sTREM2 by ELISA in the presence or absence of the cytokine IL-4 as previously described (26) . IL-4-mediated macrophage stimulation results in upregulation of TREM2 and MS4A4A (41) . sTREM2 was detected in the macrophage media beginning at day 3-post isolation and sTREM2 levels increased progressively with time in culture (Supplementary Figure S9) . On day 7, stimulation with IL-4 significantly increased levels of sTREM2 in the media ( Figure 4A ). Next, we evaluated whether antibody-mediated targeting of MS4A4A or MS4A6A would impact sTREM2 levels. Human macrophages were treated with commercially available antibodies to MS4A4A, MS4A6A, and isotope controls (see methods for details) on day 7 and sTREM2 was measured in the media 48 hours after treatment. We found that antibodies directed to MS4A4A [N-terminal cytoplasmic domain (A) and extracellular domain (B)] were sufficient to significantly reduce extracellular sTREM2 levels (Fig. 4B) . Treatment of human macrophages with an MS4A6A
antibody (N-terminal cytoplasmic domain) failed to alter sTREM2 levels (Fig. 4B) . We observed similar results when macrophages were stimulated with IL-4 (Fig. 4B) . Thus, targeting MS4A4A
with specific antibodies is sufficient to modify sTREM2 levels under basal conditions and with stimulus. However, due to limited availability of MS4A6A reagents, we cannot yet exclude the possibility that antibodies engaging extracellular epitopes on MS4A6A could also impact sTREM2 levels. 
MS4A4 co-localizes with TREM2 in human macrophages
To determine whether MS4A4A are localized within similar cellular compartments with TREM2, we performed immunocytochemistry in human macrophages. MS4A4A has been previously shown to localize on monocyte/macrophages plasma membrane (41) and on the plasma membrane and intracellular organelles in human mast cells, where it may play a role in intracellular protein trafficking (42) . While we observed some MS4A4A staining at the plasma membrane in the human macrophages, we detected the strongest signal in intracellular organelles mainly localized in the juxta-nuclear region (Fig. 4C ). Confocal analysis revealed that MS4A4A
and TREM2 co-localize in the same intracellular structures and, to a lesser extent, on the plasma membrane (Fig. 4C) . Consistent with the sTREM2 findings and previous reports (40, 41) , IL-4-mediated stimulation of the human macrophages significantly increased expression of both MS4A4A and TREM2 (Fig. S9 ).
Discussion
In this study, we performed a genome-wide analysis for genetic modifiers of CSF sTREM2 levels. We observed two independent signals in the MS4A gene region that pass genome-wide significance thresholds for association with CSF sTREM2 levels: rs1582763 and rs6591561 (MS4A4A p.M159V). Importantly, rs1582763 is associated with elevated CSF sTREM2 levels and reduced AD risk (43) and delayed age-at-onset (39) . Conversely, rs6591561
encoding MS4A4A p.M159V is associated with reduced CSF sTREM2 levels and increased AD risk and accelerated age-at-onset (39) . These SNPs modify MS4A4A and MS4A6A in human blood and brain tissue and are highly correlated with TREM2 gene expression. In human macrophages, MS4A4A and TREM2 co-localize in intracellular compartments and antibodymediated targeting of MS4A4A results in a significant reduction of sTREM2. Thus, we present genetic, molecular, and functional studies that suggest that MS4A genes are key regulators of sTREM2.
Our findings that variants in the MS4A gene region are associated with CSF sTREM2 levels provides a biological connection between the MS4A gene cluster, TREM2, and AD risk.
Prior to this study, TREM2 has been directly implicated in AD through the identification of rare variants that increase AD risk (1, 2). However, the role of TREM2 in sporadic disease was less clear. Common variants in the MS4A locus are associated with AD risk (rs1582763, OR = 0.898, P = 1.81×10 -15 ) (43) and delayed age-at-onset (HR = 0.929, P = 9.26×10 -9 ) (39), but the functional variant and mechanism of action has been unknown until now. Here, we show that variants within this AD risk locus modify CSF sTREM2 levels. Previous research has already suggested that changes in sTREM2 levels, or TREM2 biology in general, are likely involved in disease pathology (12) (13) (14) (15) (16) (17) (18) 24) . These MS4A variants also impact MS4A4A and MS4A6A expression in human blood and brain tissue, as previously reported (44, 45) .
The two independent signals in the MS4A gene region have opposing effects on CSF sTREM2 levels, which has important implications for MS4A and TREM2 biology in AD pathogenesis. Interestingly, studies in AD mouse models suggest that loss of Trem2 has opposing effects on amyloid-and tau-mediated pathology (14, 16, 46) . How CSF sTREM2 levels change throughout human disease remains poorly understood and is an area of active investigation.
However, our findings that a SNP, rs1582763, which is associated with elevated CSF sTREM2 levels is also associated with reduced AD risk and delayed age-at-onset point to a protective role for sTREM2 in AD. Consistently, the second independent SNP, rs6591561, is associated with reduced CSF sTREM2 levels, increased AD risk, and accelerated age-at-onset, suggesting that lower CSF sTREM2 is associated with a more severe disease course. We cannot say yet whether CSF sTREM2 levels are a biomarker for inflammatory or other non-specific processes in the brain, or whether CSF sTREM2 levels more directly contribute to disease pathology.
We still have a poor understanding of the origin and function of sTREM2. Three distinct transcripts for TREM2 were found in human brain tissue, including a short transcript alternatively spliced to exclude exon 4 thus encoding the transmembrane domain predicted for sTREM2 (6) . Recently a cleavage site was found on TREM2 that is cleaved by ADAM10, ADAM17, to generate sTREM2 (20, 21) . The majority of studies of the role of TREM2 in AD pathogenesis have focused on characterizing the functional impact of TREM2 rare risk variants by using animal and cell models. Some researchers suggest that sTREM2 functions to bind to and sequester TREM2 ligands, such as apolipoproteins, thus preventing them from activating the TREM2 receptor (47, 48) . Others propose that sTREM2 functions independently of the TREM2 receptor, as the introduction of sTREM2 alters microglia survival and cytokine release in Trem2 We present two lines of evidence suggesting that genes within the MS4A cluster regulate sTREM2. First, the strength of the signal in MS4A gene locus and the consistent association across datasets (P meta = 4.48×10 -21 ; Fig 2) . For comparison, the effect size (OR = 3.34; 95% CI = 2.37 -4.82) of rs1582763 on CSF sTREM2 levels is similar to that of the APOE genotype on CSF Aβ 42 levels (OR = 2.84; 95% CI = 2.30 -3.50). Second, the MS4A association with CSF sTREM2 levels represents a trans effect: TREM2 is located on chromosome 9 and this MS4A locus is on chromosome 11. As our group and others have reported, it is not common to find trans-protein quantitative trait loci (pQTLs) with large effect sizes (35, (50) (51) (52) (53) (54) . Most transpQTLs occur in genes which encode receptors or that have other regulatory influences on the protein studied. For example, variants located on 3p21.31 were significantly associated (rs145617407: β = 0.348, P = 2.58×10 -10 ) with plasma levels of macrophage inflammatory protein 1beta (MIP1b), a protein which is encoded by C-C motif chemokine ligand 4 (CCL4) located on 17q12 (50, 54) . The 3p21.31 locus contains genes which encode five members of the C-C motif chemokine receptor family (CCR1, CCR2, CCR3, CCR5, and CCR9) including a known receptor for CCL4 (CCR5) (55) . Thus, we hypothesize that one or more genes within the MS4A locus are key regulators of sTREM2.
Our study also implicates MS4A4A as a potential therapeutic target for AD. MS4A4A
co-localizes with TREM2 in human macrophages and both proteins are upregulated in response to IL-4-mediated stimulation. TREM2 and MS4A4A are highly expressed in human microglia (37) . While little is known of MS4A4A function in the brain, MS4A4A may be involved in protein trafficking and clathrin-dependent endocytosis (42) . Our findings that antibody-mediated targeting of MS4A4A was sufficient to reduce sTREM2 levels in human macrophages illustrates a putative relationship between these two proteins. Additional studies are needed to fully understand the mechanism for which MS4A4A affects sTREM2 levels. Compounds that impact MS4A4A levels or block its function could modify AD risk, by regulating brain sTREM2 levels.
Materials and Methods

Ethics statement
The Institutional Review Boards of all participating institutions approved the study and research was carried out in accordance with the approved protocols. Written informed consent was obtained from participants or their family members.
Cohort demographics
Cerebrospinal fluid was obtained from the Alzheimer Disease Neuroimaging Initiative RNA-seq data were obtained from four independent cohorts as described previously (36) .
The Knight ADRC provided data from 28 brains taken from neuropathologically-confirmed lateonset AD, an additional 10 AD cases with known TREM2 mutations, and 14 cognitively healthy controls. DIAN provided data from 19 autosomal-dominantly inherited early-onset AD. RNA extraction and sequencing methods were described previously (36) . RNA-seq data were obtained from the Mayo Clinic Brain Bank via the AMP-AD Knowledge portal (https://www.synapse.org; synapse ID = 5550404; accessed January 2017), the RNA extraction and sequencing methods were described previously (56) . The AMP-AD portal was also utilized to obtain RNA-seq data from the Mount Sinai Brain Bank (https://www.synapse.org; synapse ID = 3157743; accessed January 2017) which included data from 1,030 samples collected from four brain regions taken from 300 individuals, as described previously (57) . QC and processing was performing as previously described and additional information is in the supplementary methods (36) .
ELISA for CSF sTREM2
CSF samples were obtained and measured separately by investigators at WashU and LMU using two different methods as described below. Measured CSF levels were corrected by plate-specific correction factors by each group and corrected values were used for analyses.
Pearson's correlation was used to compare the corrected sTREM2 values between the two different ELISA methods in overlapping samples (N = 980, r = 0.834, P = 2.2×10 -254 ).
The soluble TREM2 ELISA performed at WashU was developed in-house as described previously (23) Interassay variability was calculated from duplicate internal standards across 27 plates (CV = 24.01), intra-assay variability from duplicate measurements was < 9.5%.
CSF sTREM2 measurements LMU were done with an ELISA based on the MSD platform and it is comprehensively described in previous publications (12, 24, 25) . This dilution was previously selected because it showed the best recovery and linearity performance (12) . Plates were again washed four times with washing buffer before incubation for 1 hour at RT with detection antibody. After four additional washing steps, plates were incubated with SULFO-tag conjugated secondary antibody for 1 hour in the dark at RT. Last, plates were washed four times with wash buffer followed by two washing steps in PBS. The 
Genotyping and imputation
Samples were genotyped with the Illumina 610 or Omniexpress chip. Stringent quality control (QC) criteria were applied to each genotyping array separately before combining genotype data. The minimum call rate for single nucleotide polymorphisms (SNPs) and individuals was 98% and autosomal SNPs not in Hardy-Weinberg equilibrium (P < 1×10 -6 ) were excluded. X-chromosome SNPs were analyzed to verify gender identification. Unanticipated duplicates and cryptic relatedness (Pihat ≥ 0.25) among samples were tested by pairwise genomewide estimates of proportion identity-by-descent, and when a pair of identical or related samples was identified, the sample from Knight-ADRC or with a higher number of variants that passed QC was prioritized. EIGENSTRAT (58) was used to calculate principal components. APOE ε 2, ε 3, and ε 4 isoforms were determined by genotyping rs7412 and rs429358 using Taqman genotyping technology as previously described (59) (60) (61) . The 1000 Genomes Project Phase 3 data (October 2014), SHAPEIT v2.r837 (62) , and IMPUTE2 v2.3.2 (63) were used for phasing and imputation. Individual genotypes imputed with probability < 0.90 were set to missing and imputed genotypes with probability ≥ 0.90 were analyzed as fully observed. Genotyped and imputed variants with MAF < 0.02 or IMPUTE2 information score < 0.30 were excluded, leaving 7,320,475 variants for analyses.
Statistical methods
Statistical analyses and data visualization were performed in R v3.4.0 (64), PLINK v1.9 (65) , and LocusZoom v1.3 (66) . Corrected raw values for CSF sTREM2 were normally distributed, so two-sample t-tests were used to compare CSF levels between males and females and between AD cases and controls. Pearson's product moment correlation coefficient was used for correlation analyses. Single-variant associations with CSF sTREM2 levels were tested using the additive linear regression model in PLINK v1.9 (65). Covariates were age at time of LP, sex, and the first two principal component factors to account for population structure. We run a GWAS with the CSF sTREM2 measures from both WashU and LMU. In both cases a genomewide signal in the MS4 cluster were found (See Figure 1 and Supplementary Figure S3) . The genomic inflation factor was λ < 1.008 for all of the genetic analyses. Statistical significance for single-variant analyses was selected based on the commonly used threshold estimated from
Bonferroni correction of the likely number of independent tests in genome-wide analyses (P < 5 × 10 -8 ). To identify additional independent genetic signals, conditional analyses were conducted by adding the SNP with the smallest p-value as a covariate into the default regression model and testing all remaining regional SNPs for association. The dataset was stratified by the most recently reported case status and the genetic signals from the joint dataset were tested to determine whether the genetic associations were driven by cases or controls. To determine whether the identified genetic association within the joint dataset was sex-specific, the dataset was stratified by sex and each sex was tested for the association. Results from the sex-specific analyses were verified in a subset of age-matched samples (N = 367 each for males and females, Table S1 ). Gene expression was inferred using Salmon v0.7.2 (67) transcript expression quantification of the coding transcripts of Homo sapiens included in the GENCODE reference genome (GRCh37.75). Gene counts data were transformed to stabilize expression variances along the range of mean values and normalized according to library size using the variance stabilizing transformation (VST) function in DESeq2 (68) . Correlations between expression of TREM2 and each member of the MS4A gene family, with an average TPM > 1, were tested in each independent RNA-seq cohort.
Bioinformatics annotation
All variants below the threshold for suggestive significance (P < 1×10 -5 ) were taken forward for functional annotation using ANNOVAR version 2015-06-17 (69) and examined for potential regulatory functions using HaploReg v4.1 (70) Homo sapiens, to examine DNA elements affected by the associated SNPs.
Human macrophages cultures
Peripheral blood mononuclear cells (PBMCs) were purified from human blood on FicollPaque PLUS density gradient (Amersham Biosciences, Piscataway, NJ). To generate macrophages, PBMCs were cultured in 6-well culture plates (3×10 6 cell/well) in RPMI-1640 without fetal bovine serum. After 2 hours of culture PBMCs were washed twice with PBS 1X
and cultured in RPMI supplemented with 50 ng/ml MCSF for 7 days at 37⁰C with 5% CO 2 .
Supernatants from macrophage cultures were collected at different time points, centrifuged at 21000g for 15 min and filtered through a 0.22 μ m filter to remove all cells and membrane debris.
Macrophage supernatants were then frozen in aliquots at -80°C until used in the ELISA for human sTREM2.
In vitro experiments with anti MS4A antibodies
Human macrophages after 7 days in culture were incubated with 10 µg/ml of anti- 
